USFDA approves this oral heart disease drug
Bristol Myers Squibb said on Thursday the U.S. Food and Drug Administration (USFDA) approved its oral heart disease drug Mavacamten, making it the first cardiac myosin inhibitor to be permitted for use in the…
Bharat Parenterals gets DCGI nod for Favipiravir oral suspension
Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients. The company has received licence…
Optimus Pharma gets DCGI nod for Phase III trials of Molnupiravir
Optimus Pharma received DCGI nod for conducting Phase III clinical trials for orally administered Molnupiravir capsules on patients with mild to moderate C-19 patients. After developing the active pharma ingredient (API) and the formulations for the product, Optimus…
